Summary:
Northern California Research is enrolling participants for a Mild Dementia/Alzheimer's Disease study. The purpose of this study is to see if daily doses of a study medication will improve the symptoms of mild dementia due to Alzheimer's disease. This study medication has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in your body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Alzheimer's disease. This will be assessed by completing a series of assessments where you will be asked questions by the study staff and you will be asked to write down or verbally say the answers.
The design of the study is double-blind, randomized and placebo controlled. A "double blind" study means that the study doctor and the participants who take part won't know which group is administered the study medication and which group is administered placebo. You will not have to stop taking any medications you are currently taking for your cognitive symptoms such as memantine or donepezil; however, you must be on a stable dose or 3 months.
Qualified Participants Must:
• Be 50 years of age or older
•
Have a study partner who spends 10 hours in contact with you per week and would be willing to accompany you to all study visits
Qualified Participants May Receive:
All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided. Please fill out the survey and we will be contacting you to provide study specific information.